In mouse intestinal tumors induced by the inhibition of APC, the restoration of APC function causes complete tumor regression with normal differentiation and return of stem cell function irrespective of whether tumors also carried mutations in Kras and p53. These findings by Dow et al. validate the Wnt pathway as an exquisite target for intervention.
Effective cancer treatments require targets that upon inactivation cause tumor cell death, senescence, or that force cells to differentiate. The dependence of tumors on such targets, which are usually instrumental in conferring aberrant signaling, has been coined ''oncogene addiction,'' implying that tumor cell growth will be preferentially impaired upon inhibition of such targets. Addiction to the inactivation of tumor suppressor genes is less well documented as restoration of function is more difficult to assess. For Myc-driven lymphomas lacking functional p53, restoration of p53 results in tumor cell apoptosis, yet mutations in p53 or other components in the pathway occur easily (Martins et al., 2006) . In comparison, in a Kras-driven model of nonsmall-cell lung cancer, restoration of p53 had very little effect (Junttila et al., 2010) . In this issue of Cell, Dow et al. (2015) address the dependence of mouse intestinal cancer on the loss of the tumor suppression by APC. Different tumor types often show an idiosyncratic mutation pattern with a preponderance of mutations in a distinct gene or pathway, indicative of different wiring. For instance, pancreatic cancers almost invariably carry mutations in K-RAS, whereas small-cell lung cancer shows loss-of-function of the retinoblastoma protein. Similarly, colon carcinomas predominantly bear inactivating mutations in APC (a negative regulator of beta-catenin in the Wnt pathway). One has to assume that these predominant lesions are a requirement for the development of that specific tumor. However, the question is whether these tumors also require these lesions for their maintenance, a critical issue for designing targeted interventions.
The notion that a range of additional, often quite diverse, driver mutations are found in these tumors further complicates matters as these additional lesions could abrogate the dependency on the initial defect. The question of addiction of a progressed tumor can best be answered by genetic experiments in which the physiological level of the supposed critical driver lesion is restored. Dow et al. use a conditional and inducible short hairpin RNA (shRNA) approach to control the level of APC in a small subset of intestinal stem cells in the mouse (Figure 1 ). Reducing APC to very low levels results in tumors along the intestine including colon. Once tumors are detectable by endoscopy, they restore normal levels of APC by switching off the shRNA. This results in tumor regression. Tumor cells undergo differentiation toward the cell types specified by normal intestinal differentiation. Remarkably, this also occurs in tumors that, besides expressing reduced APC levels, lack p53 and bear a dominant active Kras. This illustrates that loss of APC remains critical for intestinal tumor maintenance even if potent additional oncogenic lesions have been acquired that are known to cause tumor progression in this system. This implies that cellular processes unleashed by APC loss are appealing targets for intervention. The observation made in a small fraction of patients that beta-catenin mutations are found rather than loss-of-function lesions in APC suggests that beta-catenin or the complexes it forms with other transcription regulators could be suitable targets for drug intervention. Indeed, tankyrase inhibitors, which impair beta-catenin function in APC mutant cells by stabilizing Axin2 (Huang et al., 2009) , have shown to impede tumor development in pre-clinical models (Waaler et al., 2012 ) and are currently being tested in clinical trials.
A number of observations made in this study are noteworthy. First of all, the authors do not see any non-responding tumors or eventual relapses in their model, even if APC is restored in the mutant Kras, p53 setting. A case in point is the Myc transcription factor. Myc is a critical driver in many tumors, and abrogation of its transcription activating capacity results invariably in tumor regression with no sign of escapees (Soucek et al., 2008 (Soucek et al., , 2013 . In the case of APC, this lack of escape might be due to the fact that APC constitutes a critical node of the Wnt and other signaling pathways and escape by mutations in APC would require almost complete suppression of its activity, at least in this tumor type. In the study by Dow et al., the required loss-of-function of both alleles might be unlikely to occur in view of the relatively modest tumor mass inherent to mouse models. In the same vein, activation of beta-catenin requires specific mutations, also making the probability low and given its downstream position in the signaling pathway alternative lesions might not be at hand. It would be of interest to see if one can force escapees in this system, for instance, by mutagenesis, and what their nature would be. Furthermore, the fact that APC controls the degradation of multiple factors regulating cell proliferation might add to the strong selection for APC deletions and therefore its critical role in colorectal cancer. The Hippo pathway, another signaling cascade highly relevant in cancer (Harvey et al., 2013) , is also controlled by the APC destruction complex and contributes to the oncogenic capacity of APC loss (Azzolin et al., 2014) .
Second, the study shows that the extent of APC reduction is a critical factor. Only the most active shRNAs elicit tumor development. Still, the tumor latency is significantly longer than observed for genetic deletion of Apc. This indicates that even very low levels of this tumor suppressor protein can substantially impair tumor development. It also stresses the requirement for robust shRNA strategies to prove addiction. The authors also make another remarkable observation. Whereas genetic APC ablation in mice results in tumors largely in the small intestine (Boivin et al., 2003) -an observation often used to question the utility of the mouse as a model for colon carcinomas-the shRNA-mediated inhibition of APC also gives rise to many colon tumors, suggesting that the level of this tumor suppressor protein matters and might be a factor in the preponderance of the specific tumor subtype that arises. Obviously such subtleties can also be brought about by specific mutations in APC, and it will be worthwhile to more closely assess the effects of individual mutations in this regard.
Third, the change brought about by restoring normal APC levels in the tumors, even those carrying the Kras and p53 lesions, is remarkable. Cells would stop proliferation and resume their differentiation program, expressing the markers normally found in the intestine. Even more surprising, the tumor cells that are marked by fluorescent protein appear capable of resuming normal crypt stem cell function, giving rise over time to fully fluorescent reporter-labeled normal crypts. Relatively few normal reporter-labeled crypts are found upon regression. Possibly this relates to a relatively small fraction of tumor cells that are capable of resuming a normal stem cell role or to the limited access to the micro-environmental signals required for such a role. Therefore, it would be of interest to follow the remodeling in these tumors toward normal functionality over time with a number of markers that define the different cell types in the colon and that read out MAPK pathway activation.
Altogether, this study elegantly shows the power of mouse models to give insight into the role of tumor-causing lesions, their role in tumor maintenance, their dependence, or lack thereof, on other co-occurring mutations, and the consequences of restoring normal function. 
